Efeitos cardiorrespiratórios e comportamentais da dexmedetomidina, associada ou não à meperidina, em jumentos nordestinos (Equus asinus)
Carregando...
Data
2017-02-20
Autores
Yamada, Diego Iwao [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
O uso de associações de agonistas adrenérgicos α-2 e opioides para obtenção de efeitos neuroleptoanalgésicos é amplamente estudado. Entretanto, poucos estudos foram descritos em asininos. Diante do exposto, objetivou-se estudar a eficácia da associação de dexmedetomidina e meperidina em jumentos. Foram utilizados cinco jumentos, SRD, um macho e quatro fêmeas, pesando entre 104 e 150 kg, submetidos aleatoriamente a quatro protocolos experimentais com intervalo de 15 dias entre eles: Tratamento DM - dexmedetomidina (0,005 mg/kg) IV e meperidina (4 mg/kg) IM; tratamento C - administração de placebo IV e IM; tratamento D - dexmedetomidina (0,005 mg/kg) IV e placebo IM e tratamento M – placebo IV e meperidina (4 mg/kg) IM. Foram avaliadas FC, f, PAS, PAD, PAM, PVC, IC, IS, IRVP, pH, PaO2, PaCO2, SaO2, temperatura corpórea, altura de cabeça, sedação, ataxia e motilidade intestinal, antes e após 5, 10, 20, 30, 45 e 60 minutos das administrações dos tratamentos. Observou-se redução entre 55% e 70% nas medidas de altura de cabeça (p<0,05) respectivamente nos tratamentos D e DM. Para esses observou-se diminuição da frequência respiratória (p<0,05) a partir de 5 e 20 minutos, respectivamente, sem alterações nas PaO2, PaCO2 e pH. Houve diminuição do IC nos tratamentos D e DM em relação ao tratamento C após 5 minutos, e nos tratamentos D e M, após 10 minutos da administração. Assume-se que a associação neuroleptoanalgésicas de dexmedetomidina e meperidina promove sedação satisfatória com mínimos efeitos cardiorrespiratórios e hemogasométricos em jumentos hígidos.
The neuroleptoanalgesic effects of opioids and alpha-2 adrenergic agonists have been widely studied in horses. However, there is a paucity of information regarding this association in donkeys. Therefore, we ought to evaluated the neuroleptic association of dexmedetomidine and meperidina in these species. Five mixed-breed donkeys, one male and four female, weighting between 104 to 155kg were used on the study. The animals were submitted to four treatments in a randomized crossover study, with a minimun of 15 days between treatments of washout period. Treatment protocols were stablished as follows: treatment DM - dexmedetomidine (0,005 mg/kg) IV and meperidine (4 mg/kg) IM; treatment C - placebo IV and IM; Group D: dexmedetomidine (0,005 mg/kg) IV and placebo IM; Group M: placebo IV and meperidine (4mg/kg) IM. There were evaluated HR, RR, SAP, DAP, MAP, CVP, cardiac output indexed to weight, stroke volume indexed to weight, periferic resistance indexed to weight, pH, PaO2, PaCO2, SaO2, body temperature, head height, sedation, ataxia and intestinal motility before and 5, 10, 20, 30, 45, 60 minutes after administration of treatments. There was a reduction of 55% and 70% in head height values (p<0.05) in groups D and DM, respectively. In these same treatments, respiratory rate decreased (p<0.05) 5 and 20 minutes after treatment in groups D and DM, repectively. The CI was decreased in treatments D and DM compared to treatment C 5 minutes after administration, and in treatments D and M after 10 minutes of administration. In conclusion, the neuroleptoanalgesic association of dexmedetomidine and meperidine promotes satisfactory sedation with minimal effects on cardiorespiratory, hemodynamic and blood gas parameter in healthy donkeys.
The neuroleptoanalgesic effects of opioids and alpha-2 adrenergic agonists have been widely studied in horses. However, there is a paucity of information regarding this association in donkeys. Therefore, we ought to evaluated the neuroleptic association of dexmedetomidine and meperidina in these species. Five mixed-breed donkeys, one male and four female, weighting between 104 to 155kg were used on the study. The animals were submitted to four treatments in a randomized crossover study, with a minimun of 15 days between treatments of washout period. Treatment protocols were stablished as follows: treatment DM - dexmedetomidine (0,005 mg/kg) IV and meperidine (4 mg/kg) IM; treatment C - placebo IV and IM; Group D: dexmedetomidine (0,005 mg/kg) IV and placebo IM; Group M: placebo IV and meperidine (4mg/kg) IM. There were evaluated HR, RR, SAP, DAP, MAP, CVP, cardiac output indexed to weight, stroke volume indexed to weight, periferic resistance indexed to weight, pH, PaO2, PaCO2, SaO2, body temperature, head height, sedation, ataxia and intestinal motility before and 5, 10, 20, 30, 45, 60 minutes after administration of treatments. There was a reduction of 55% and 70% in head height values (p<0.05) in groups D and DM, respectively. In these same treatments, respiratory rate decreased (p<0.05) 5 and 20 minutes after treatment in groups D and DM, repectively. The CI was decreased in treatments D and DM compared to treatment C 5 minutes after administration, and in treatments D and M after 10 minutes of administration. In conclusion, the neuroleptoanalgesic association of dexmedetomidine and meperidine promotes satisfactory sedation with minimal effects on cardiorespiratory, hemodynamic and blood gas parameter in healthy donkeys.
Descrição
Palavras-chave
Agonistas adrenérgicos alfa-2, Débito cardíaco, Pressão arterial, Sedação, Termodiluição, α-2 adrenergic agonists, Arterial pressure, Cardiac output, Sedation, Thermodilution